Approved Antiviral Drugs over the Past 50 Years
Top Cited Papers
Open Access
- 1 July 2016
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 29 (3), 695-747
- https://doi.org/10.1128/cmr.00102-15
Abstract
SUMMARY Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2′-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2′-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox). Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.Keywords
This publication has 185 references indexed in Scilit:
- HIV-1 entry inhibitors: recent development and clinical useCurrent Opinion in Virology, 2013
- Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination eraBiochemical Pharmacology, 2012
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyJournal of Hepatology, 2009
- The discovery of antiviral agents: Ten different compounds, ten different storiesMedicinal Research Reviews, 2008
- Human cytomegalovirus virion proteinsHuman Immunology, 2004
- FoscarnetDrugs, 1991
- Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivativeBiochemical and Biophysical Research Communications, 1989
- Successful Treatment with Foscarnet of an Acyclovir-Resistant Mucocutaneous Infection with Herpes Simplex Virus in a Patient with Acquired Immunodeficiency SyndromeThe New England Journal of Medicine, 1989
- Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitroBiochemical and Biophysical Research Communications, 1987
- Isolation of a New Virus, HBLV, in Patients with Lymphoproliferative DisordersScience, 1986